Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents

2015 ◽  
Vol 26 (3) ◽  
pp. 259-265 ◽  
Author(s):  
Li Qi-Hua ◽  
Zhang Qi ◽  
Zhi Yu ◽  
Li Xiao-Long ◽  
Ji Hai-Gang ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Second Generation ◽  
Term Effect ◽  
Drug Eluting Stents ◽  
Long Term Effect ◽  
Drug Eluting ◽  
Artery Disease

scholarly journals TCT-198 Comparing Long-term Outcomes of First-Generation and Second-Generation Drug Eluting Stents in Patients with Coronary Artery Disease

2018 ◽  
Vol 72 (13) ◽  
pp. B84
Author(s):  
Parth Parikh ◽  
Kinjal Banerjee ◽  
Amar Krishnaswamy ◽  
ravi nair ◽  
Russell Raymond ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
First Generation ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Long Term Outcomes ◽  
Drug Eluting ◽  
Artery Disease

Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Drug-Eluting Stents for Patients With Coronary Artery Disease: An Update Meta-Analysis

2014 ◽  
Vol 28 (4) ◽  
pp. 379-385 ◽  
Author(s):  
Yanyu Wang ◽  
Pingshuan Dong ◽  
Ling Li ◽  
Xiaoling Li ◽  
Hongyun Wang ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Biodegradable Polymer ◽  
Second Generation ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Drug Eluting ◽  
Artery Disease

Long-term effect of rehabilitation in coronary artery disease patients: randomized clinical trial of the impact of exercise volume

2010 ◽  
Vol 24 (4) ◽  
pp. 319-327 ◽  
Author(s):  
Dominique Hansen ◽  
Paul Dendale ◽  
Anita Raskin ◽  
Annick Schoonis ◽  
Jan Berger ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Clinical Trial ◽  
Coronary Artery ◽  
Randomized Clinical Trial ◽  
Term Effect ◽  
Long Term Effect ◽  
Artery Disease ◽  
The Impact

scholarly journals Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis

2018 ◽  
Vol 1 (11) ◽  
pp. e93 ◽  
Author(s):  
James J. Wu ◽  
Joshua A.H. Way ◽  
Probal Roy ◽  
Andy Yong ◽  
Harry Lowe ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Biodegradable Polymer ◽  
Second Generation ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Durable Polymer ◽  
Drug Eluting ◽  
Artery Disease

Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial

The Lancet ◽  
2020 ◽  
Vol 396 (10261) ◽  
pp. 1504-1510 ◽  
Author(s):  
Raban V Jeger ◽  
Ahmed Farah ◽  
Marc-Alexander Ohlow ◽  
Norman Mangner ◽  
Sven Möbius-Winkler ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Drug Eluting Stents ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Drug Eluting ◽  
Artery Disease

scholarly journals Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease

Circulation ◽  
2018 ◽  
Vol 138 (20) ◽  
pp. 2216-2226 ◽  
Author(s):  
Sripal Bangalore ◽  
Bora Toklu ◽  
Neil Patel ◽  
Frederick Feit ◽  
Gregg W. Stone
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Drug Eluting ◽  
Artery Disease

Cost-effectiveness

ESC CardioMed ◽  
2018 ◽  
pp. 1395-1399
Author(s):  
Ruben L. J. Osnabrugge ◽  
A. Pieter Kappetein
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Drug Eluting Stents ◽  
Long Term Follow Up ◽  
Drug Eluting ◽  
Artery Disease ◽  
The Cost

Approximately 2% of the total healthcare expenditure in the European Union is spent on coronary artery disease and these expenditures are expected to increase. In order to make rational decisions on resource allocation, clinical and economic outcomes of treatment strategies need to be analysed together. Cost-effectiveness studies provide a framework for making such decisions. The early economic studies comparing balloon angioplasty with coronary artery bypass grafting (CABG) show that the early cost benefit of angioplasty is lost at long-term follow-up. CABG provides a clinically and economically attractive treatment option in patients with severe coronary artery disease. Later studies with bare-metal or drug eluting stents showed that the higher invasiveness of CABG leads to a longer hospital stay and higher upfront costs. However, at longer follow-up the cost difference is small and clinical outcomes with CABG are better than with percutaneous coronary intervention (PCI). This makes CABG superior to PCI at long-term follow-up, both clinically and economically in patients with extensive coronary disease. Nevertheless, in patients with less complex coronary artery disease, PCI with drug-eluting stents may be preferred on both clinical and economic grounds. Although reduction in stent price does not have a big impact, several other developments may impact future economic comparisons between PCI and CABG. Newer-generation stents will enhance the clinical and economic profile of PCI. Moreover, better clinical decision-making tools and fractional flow reserve will impact the cost-effectiveness equation.

Sign in / Sign up

Export Citation Format

Share Document